Ashley Chan

Tanya Gupta, MD, highlights the utility of adjuvant CDK4/6 and PARP inhibitors in patients with HR-positive, HER2-negative breast cancer.

Aditya Shreenivas, MD, MS, discusses the association between Claudin 18 and MUC1 biomarkers and ongoing targeted therapy challenges.

Andreas M. Kaiser, MD, discusses the differences between minimally invasive surgical approaches for colorectal cancer in community vs academic settings.

Patients with relapsed/refractory MCL who opted for elective treatment interruptions from venetoclax/ibrutinib experienced durable responses.

Palbociclib plus letrozole prolonged PFS compared with placebo plus letrozole in patients with ER-positive advanced endometrial cancer.

Preclinical cytotoxicity was demonstrated with anti-CD38-CAR-gamma-delta T cells in multiple myeloma.

John M. Burke, MD, discusses identified challenges in the initiation of venetoclax in patients with CLL within a community-based setting.

Vepdegestrant improved PFS in ESR1-mutated, ER-positive, HER2-negative metastatic breast cancer, but PFS was not improved in the ITT population.

Same-day administration of eflapegrastim and cycle 1 of chemotherapy reduced the mean duration of severe neutropenia in early-stage breast cancer.

Palbociclib plus an AI prolonged OS and PFS in real-world patients with HR-positive/HER2-negative breast cancer from disadvantaged neighborhoods.

Sewit Teckie, MD, discusses the advantages and disadvantages of a cfDNA blood-based assay compared with colonoscopy in diagnosing colorectal cancer.

The FDA granted RMAT designation to nogapendekin alfa inbakicept/CAR-NK for lymphopenia reversal in patients with advanced or metastatic pancreatic cancer.

Treatment with ivosidenib plus CPX-351 showed early efficacy in patients with relapsed/refractory AML or high-risk MDS harboring an IDH1 mutation.

Hedyeh Ebrahimi, MD, MPH, highlights the early activity of CBM588 plus cabozantinib/nivolumab for the treatment of patients with metastatic RCC.

The CHMP has recommended the approval of perioperative durvalumab plus neoadjuvant chemotherapy for patients with resectable NSCLC.

Angela Jain, MD, discussed the current treatment paradigm in triple-negative breast cancer (TNBC), including currently investigated therapies, during TNBC Awareness Day.

Charles B. Nguyen, MD, provides insight into current challenges faced in the non–clear cell RCC landscape beyond the NCCN’s recent guideline updates.

The resubmission of a BLA for odronextamab was accepted by the FDA for the treatment of patients with relapsed/refractory follicular lymphoma.

At 5 years of follow-up, sustained disease control was demonstrated with ibrutinib plus venetoclax and obinutuzumab in patients with newly diagnosed MCL.

Time-limited zanubrutinib/rituximab was well tolerated and continued to elicit remissions 13 months after treatment discontinuation in treatment-naive CLL.

The FDA has granted the novel, oral KAT2A/B degrader AUTX-703 fast track designation for the treatment of patients with relapsed/refractory AML.

Gentry King, MD, discusses positive and negative outcomes following the phase 3 CELESTIAL and COSMIC-312 trials in patients with hepatocellular carcinoma.

Julie M. Vose, MD, MBA, discusses the 3-year follow-up data with epcoritamab in patients with relapsed/refractory diffuse large B-cell lymphoma.

Gentry King, MD, highlights the evolution of treatments in the hepatocellular carcinoma landscape and the impact of the phase 3 HIMALAYA trial.

R. Lor Randall, MD, FACS, discusses the enrollment criteria for a trial investigating surgical outcomes in patients with proximal femur metastases.

Neeta Somaiah, MD, highlights the evolving sarcoma treatment paradigm within the past 5 years, including the FDA approval of afamitresgene autoleucel.

The FDA has accepted and granted priority review to an NDA for dordaviprone in recurrent H3K28M-mutant diffuse glioma.

No significant differences in PROs were shown between the tivozanib/nivolumab and tivozanib monotherapy arms in patients with advanced clear cell RCC.

MRD-negative remissions with obe-cel were more durable and associated with higher EFS and OS rates vs MRD-positive remissions in relapsed/refractory B-ALL.

First-line therapy with olaparib plus abiraterone demonstrated clinical benefit in rPFS and OS in mCRPC harboring germline and somatic BRCA mutations.